Does UTMD pay a dividend and is it safe?

Utah Medical Products Inc. (UTMD) offers a 1.87% cash dividend yield ($1.32 annualized) and 3.67% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.

Stock Ratings / Health Care / UTMD / dividends

KTWO (56) PROF (40) PDEX (54) OSUR (31) ⌘ Pro Terminal →

Utah Medical Products Inc. (UTMD) Dividend Safety Gauge & 10-Year DRIP Compounder

$70.55 +3.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $70.88

Utah Medical Products Inc. (UTMD) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $216.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on UTMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is UTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Utah Medical Products Inc. (NASDAQ: UTMD) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $70.55 (+3.64% 1D, market cap $216.7M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, UTMD ranks #152 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does UTMD compare to KTWO and PROF in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), UTMD carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of 57.1%, and ROIC of 26.9%. By comparison, KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) holds a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M) and PROF (Profound Medical Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $240.0M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for UTMD?

▼

Per UTMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000706698), Utah Medical Products Inc. generated $38.5M in revenue (-5.8% YoY), $0 in net income, and $14.3M in free cash flow against $122.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (57.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $70.88 (+0.47%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 37.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+1.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UTMD)Realized 20D OHLCV Swing Band: ±4%

Deterministic 5-Pillar Attribution (62/100 Composite)

🔍 WHY UTMD SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 37.2% FCF Margin ($14.3M FCF) & 57.1% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$74.71+0.5% Next Q

Q2 (-2Q)

Grade B-$75.07-2.7% Next Q

Q3 (-1Q)

Grade C+$73.06-3.4% Next Q

Current

Grade C$70.55+0.7% Hist 90D α

Trajectory: B (70) → C (62)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the UTMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, UTMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 54.6% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.73) or 200D SMA ($68.14) invalidates the momentum regime and cuts Target Base ($71.82) toward Bear Floor ($56.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $UTMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “UTMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 62%NO 38%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

3.67% Total Yield

1.87% Cash ($1.32/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

88/100 • FORTRESS PAYOUT

FREE CASH FLOW PAYOUT RATIO

18.1% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.2% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $20,042

Est. Year-10 Shareholder Yield: $736/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.5K

Yr 2

$12.3K

Yr 3

$13.2K

Yr 4

$14.2K

Yr 5

$15.2K

Yr 6

$16.3K

Yr 7

$17.4K

Yr 8

$18.7K

Yr 9

$20.0K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in UTMD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on UTMD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

UTMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.13%📐 HORIZONTAL RANGE

2026-11-03O $66.81H $70.55L $66.81C $70.55VOL 42.8K

RES: $78.50SUP: $66.50SMA50: $72.73SMA200: $68.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

UTMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 UTMD Butterfly Map → + Track UTMD →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

5.0%/yr Implied 5Y Growth

vs. -5.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on UTMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for UTMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for UTMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UTMD)

Health Care Rank #152 of 1015 ⚔️ KTWO vs UTMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (UTMD vs. KTWO, PROF, PDEX, OSUR)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Utah Medical Products Inc. (UTMD) ranks #152 by composite RQD confidence (62/100, grade C) and #561 by equity capitalization ($216.7M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
UTMD ACTIVE Utah Medical Products Inc.	C	62/100	—	57.1%	26.9%	+3.64%	$216.7M	Benchmark Subject
KTWO K2 Capital Acquisition Corporation Class A Ordinary Share	D+	56/100	—	—	—	+0.20%	$202.2M	/ktwo-vs-utmd →
PROF Profound Medical Corp.	D-	40/100	—	70.8%	-35.0%	+2.44%	$240.0M	/prof-vs-utmd →
PDEX Pro-Dex Inc.	D+	54/100	22.2x	29.3%	23.2%	-0.88%	$186.1M	/pdex-vs-utmd →
OSUR OraSure Technologies Inc.	E	31/100	—	41.9%	-35.0%	-12.31%	$271.7M	/osur-vs-utmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000706698 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported GAAP revenue of $38.5M (-5.8% vs. FY2024 revenue of $40.9M , and -23.3% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $14.7M, and free cash flow of $14.3M (-1.9% YoY). On the balance sheet, UTMD closed FY2025 with $122.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$38.5M	$0	$14.7M	$14.3M	$122.5M	—
FY2024 (FY)	2024-12-31	$40.9M	$0	$14.8M	$14.6M	$122.5M	—
FY2023 (FY)	2023-12-31	$50.2M	$0	$22.3M	$22.3M	—	—

3. UTMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is UTMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does UTMD compare to KTWO and PROF in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for UTMD?

Where is UTMD trading relative to its 50-day, 200-day, and 52-week technical levels?

UTMD last traded at $70.55 (+3.64% on volume of 38,991 shares), positioning the stock -3.00% below its 50-day simple moving average ($72.73) and +3.54% above its 200-day simple moving average ($68.14). Across its 52-week range of $53.66 to $76.89, UTMD sits at the 72.7% percentile with a 14-day RSI of 34.2 (NEUTRAL RANGE) and an implied next-earnings move of ±4.0% ($67.73 to $73.37).

Direct Sub-Reports: UTMD RQD Cockpit UTMD 12M Forecast UTMD Earnings & Move UTMD Dividends & DRIP UTMD Insiders & 13F UTMD Whale Options UTMD Profit Sankey UTMD News & Why

ROARABLE RATING BRIEF • RQD 62/100 (C) ✓ SEC XBRL & RQD VERIFIED

UTMD — Utah Medical Products Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Utah Medical Products Inc. (UTMD) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $70.55 (+3.64% 1D, market capitalization $216.7M).

Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 26.9%, gross margin of 57.1%, operating margin of 29.6%, and free cash flow yield of 6.73%.
Whale 13F & Options Flow (6/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. (UTMD) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, with a market capitalization of $0.2B. Per the market data, the company reports a gross margin of 57.1% and an operating margin of 29.6%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Utah Medical Products Inc. (UTMD) reported $38.5M in annual revenue (up from $40.9M in FY2024, -5.8% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($50.2M revenue, $0 net income) through FY2025, UTMD scaled operating cash flow to $14.7M and free cash flow to $14.3M, backed by $122.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C • RQD 62/100): Strong cash generator (57.1% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $53.66 – $76.89 52-week range.
🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 10.8x EV/EBITDA against 29.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Medical/Dental Instruments. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data.

Key Question #1: Can UTMD sustain or expand its 29.6% operating margin and 26.9% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $38.5M and free cash flow of $14.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is UTMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

UTMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Utah Medical Products Inc. (UTMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to UTMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Utah Medical Products, Inc. Extends Tender Offer

Yahoo Finance report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Utah Medical Products, Inc. Reports Results of Tender Offer

TradingView report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

The $75-per-share offer had an effective cost of $75.36 per share for Utah Medical Products.

Stock Titan report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Utah Medical Products (UTMD) Q3 Results Highlight Revenue Pressure Beneath Strong Margins

Yahoo Finance report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Kevin L Cornwell Of Utah Medical Products Shows Optimism, Buys $66K In Stock

Benzinga report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Utah Medical Products, Inc. Reports Corrected Results of Tender Offer

TradingView report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Utah Medical Products (UTMD) Q3 Earnings Defy Revenue Drop

Simply Wall St report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Yahoo! Finance Canada report covering Utah Medical Products Inc. (UTMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

UTMD Bull vs. Bear Conversation Board — What's Your Call at $70.55?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON UTMD 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $81.70 (+20.0%)

📌 Pinned Debate

ROIC of 26.9% and a 6.73% FCF yield indicate a highly capital-efficient cash engine trading at 10.8x EV/EBITDA.

Long UTMD at $68.08 targeting $81.70. ROIC of 26.9% and a 6.73% FCF yield indicate a highly capital-efficient cash engine trading at 10.8x EV/EBITDA.. Institutional whale score is 6/20 and the risk/reward vs. the $53.66 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

Both sides have a point here — UTMD's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $52.42 (-23.0%)

Spot @ $68.08

Revenue fell from $50.2M to $38.5M over two years and net margin is 0%, while institutional flow scores only 6 of 20.

I respect the product at Utah Medical Products Inc., but the stock at $68.08 is a different story. Revenue fell from $50.2M to $38.5M over two years and net margin is 0%, while institutional flow scores only 6 of 20.. FCF yield is 6.73% and RQD sits at 62/100 (C) — why pay up here when you can wait for next quarter's numbers?